Acutus Medical, Inc.
OTCPK:AFIB Voorraadrapport
Marktkapitalisatie: US$2.4m
Acutus Medical Beheer
Beheer criteriumcontroles 2/4 Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Takeo Mukai
Algemeen directeur
US$496.8k
Totale compensatie
Percentage CEO-salaris 65.1% Dienstverband CEO 2.3yrs Eigendom CEO 0.2% Management gemiddelde ambtstermijn geen gegevens Gemiddelde ambtstermijn bestuur 4.1yrs
Recente managementupdates
Acutus Medical, Inc., Annual General Meeting, Jun 13, 2024 Apr 28
Acutus Medical, Inc. Announces Board Changes Jan 18 Acutus Medical, Inc. Announces Chief Executive Officer Changes
Acutus Medical, Inc. Announces Executive Changes Jul 06
High number of new directors Nov 16
High number of new directors Nov 02
Toon alle updates
Nasdaq Files A Form 25 Notification of Delisting with the Securities and Exchange Commission to Complete Acutus Medical, Inc.'s Delisting May 18
Acutus Medical, Inc.(NasdaqCM:AFIB) dropped from NASDAQ Composite Index May 10
Acutus Medical Provides Non-Compliance Update May 04
Acutus Medical, Inc., Annual General Meeting, Jun 13, 2024 Apr 28
New minor risk - Shareholder dilution Apr 09
New major risk - Negative shareholders equity Apr 02
Full year 2023 earnings released: US$0.41 loss per share (vs US$1.40 loss in FY 2022) Apr 02
Investors Give Acutus Medical, Inc. (NASDAQ:AFIB) Shares A 29% Hiding Feb 24
Acutus Medical, Inc. Announces Board Changes Jan 18
Market Cool On Acutus Medical, Inc.'s (NASDAQ:AFIB) Revenues Pushing Shares 43% Lower Dec 20 Acutus Medical, Inc. Announces Chief Executive Officer Changes
Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.72 loss in 3Q 2022) Nov 10
Acutus Medical, Inc. to Report Q3, 2023 Results on Nov 13, 2023 Nov 03
Acutus Medical Receives A Letter from Nasdaq Approving the Company’s Application to List Its Securities on the Nasdaq Capital Market Nov 01
Acutus Medical, Inc. Provides Revenue Guidance for the Year 2023 Aug 09
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 08
Acutus Medical, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 25
Take Care Before Diving Into The Deep End On Acutus Medical, Inc. (NASDAQ:AFIB) Jul 18
Acutus Medical, Inc. Announces Executive Changes Jul 06
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 13
Acutus Medical, Inc. Provides Revenue Guidance for the Year 2023 May 12
Acutus Medical Receives Notice from the Nasdaq Regarding Not in Compliance with Listing Rule 5450(a)(1) May 08
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 17
Acutus Medical, Inc. Announces Results from the AcQForce Flutter Study “AcQForce Flutter: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter” Feb 07 Acutus Medical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022
Price target increased to US$4.13 Jan 04
Acutus Medical Achieves Eu Mdr Submission Milestone in Sale of Left-Heart Access Portfolio to Medtronic Dec 22
Acutus Medical, Inc. Announces Full Market Release of Next Generation Software Platform AcQMap 8.5 Dec 20
High number of new directors Nov 16
Third quarter 2022 earnings: EPS exceeds analyst expectations Nov 11
Acutus Medical, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022 Nov 11
Acutus Medical Receives Non-Compliance Notice From Nasdaq Nov 07
High number of new directors Nov 02
Acutus Medical, Inc. Announces Submission of Premarket Approval Application for AcQBlate Force Sensing Ablation Catheter & System Oct 19
Acutus files for FDA approval of catheter ablation system AcQBlate Oct 18
Glancy Prongay & Murray LLP Appoints Lead Counsel in Securities Class Action Against Acutus Medical, Inc Aug 25 Acutus Medical, Inc. Announces Board Changes
Consensus forecasts updated Aug 18
Price target increased to US$3.38 Aug 13
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 12
Acutus Medical Non-GAAP EPS of -$0.93 misses by $0.17, revenue of $4.1M beats by $0.13M Aug 11
Acutus Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Jul 29
Acutus Medical Announces Approval of its AcQMap System and AcQMap 3D Imaging and Mapping Catheter in Japan Jul 28 Acutus Medical, Inc. Provides Revenue Guidance for the Second Quarter of 2022
Acutus Medical sees Q2 revenue above consensus estimate Jul 21 Acutus Medical, Inc. announced that it has received funding from Deerfield Management Company, L.P. Series C Jul 03
Medtronic plc (NYSE:MDT) completed the acquisition of Left-heart Access Portfolio from Acutus Medical, Inc. (NasdaqGS:AFIB). Jul 02
Acutus Medical, Inc. Announces FDA Clearance, Commercial Launch of AcQCross Line Extension Compatible with Watchman Delivery System Jun 28
Acutus Medical Receives Non-Compliance Notice from Nasdaq Jun 25
Consensus forecasts updated May 19 Acutus Medical, Inc. Completes Enrollment in Ide Trial with Its Acqblate® Force Sensing Ablation System
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 13
Price target decreased to US$3.50 Apr 27
High number of new directors Apr 27
Price target decreased to US$4.00 Apr 23
Acutus Medical, Inc. (NASDAQ:AFIB) Analysts Just Trimmed Their Revenue Forecasts By 25% Apr 06
Consensus revenue estimates fall by 25% Apr 06
Full year 2021 earnings: EPS exceeds analyst expectations Apr 01
Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Acutus Medical, Inc Feb 16
Acutus Medical, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2021 Jan 20
Independent Director recently bought US$151k worth of stock Nov 21
Third quarter 2021 earnings released: US$0.94 loss per share (vs US$1.95 loss in 3Q 2020) Nov 12
Price target decreased to US$16.40 Oct 22
Acutus Medical: A Name To Slowly Accumulate Sep 04
Acutus Medical, Inc. Provides Revenue Guidance for the Year 2021 Aug 15
Second quarter 2021 earnings released: US$1.02 loss per share (vs US$32.24 loss in 2Q 2020) Aug 14
AcQMap 8, Acutus Medical’s Innovative Suite of Software Upgrades, Receives FDA Clearance and CE Mark Aug 12
Acutus Medical, Inc.: Paradigm-Shifting Technology At A Shocking Price Jul 21
Acutus Medical, Inc. has completed a Follow-on Equity Offering in the amount of $77 million. Jul 16
Acutus Medical, Inc. Provides Earnings Guidance for the Second Quarter Ending June 30, 2021 Jul 14 Acutus Medical, Inc.(NasdaqGS:AFIB) dropped from Russell 3000E Value Index
Acutus Medical Receives FDA Approval to Initiate US Atrial Fibrillation IDE Trial with the AcQBlate® FORCE Sensing Ablation System May 28
Acutus Medical cleared to start atrial fibrillation IDE trial May 27
Analysts Have Been Trimming Their Acutus Medical, Inc. (NASDAQ:AFIB) Price Target After Its Latest Report May 15
First quarter 2021 earnings released: US$1.04 loss per share (vs US$25.83 loss in 1Q 2020) May 14
Acutus Medical, Inc. Provides Earnings Guidance for the Second Quarter Ending June 30, 2021 and Full Year Ending December 31, 2021 May 13
Full year 2020 earnings released: US$8.94 loss per share Mar 20 Acutus Medical, Inc. Appoints John Sheridan as A New Director
Acutus Medical, Inc. to Report Q4, 2020 Results on Mar 18, 2021 Mar 05
Acutus Medical Appoints Duane Wilder as Chief Commercial Officer Mar 04
Analyse CEO-vergoeding Hoe is Takeo Mukai's beloning veranderd ten opzichte van Acutus Medical's winst? Datum Totale vergoeding Salaris Bedrijfswinsten Jun 30 2024 n/a n/a -US$6m
Mar 31 2024 n/a n/a -US$10m
Dec 31 2023 US$497k US$323k -US$12m
Compensatie versus markt: De totale vergoeding ($USD 496.85K ) Takeo } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 648.89K ).
Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Takeo te vergelijken met de prestaties van het bedrijf.
CEO Mr. Takeo Mukai serves as Chief Financial Officer (CFO) at Acutus Medical, Inc. since January 9, 2023 and serves as its Chief Executive Officer since January 2024 and served as its Senior Vice President si ... Show more
Bestuursleden Naam Positie Tenure Compensatie Eigendom Independent Director 3.7yrs US$82.70k 0.035% $ 861.2 Independent Director 8.7yrs US$68.70k 0.042% $ 1.0k Independent Director 3.3yrs US$75.70k 0.038% $ 917.4 Independent Director 7.3yrs US$70.70k 0.042% $ 1.0k Independent Chairperson of the Board 4.5yrs US$73.70k 0.042% $ 1.0k Independent Director 2.3yrs US$78.70k 0.016% $ 382.8
Meer tonen
Ervaren bestuur: De raad van bestuur van AFIB wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
